Intra-Cellular Therapies Announces Upcoming Presentations at the 5th Biennial Schizophrenia International Research Society Conference

NEW YORK, March 30, 2016 -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that one oral presentation and three posters on ITI-007, the Company’s lead drug candidate, will be featured at the 5th Biennial Schizophrenia International Research Society (SIRS) Conference. The meeting will be held April 2-6, 2016, in Florence, Italy. 

The presentation and posters will feature data from ITI-007-301, the Company’s recently completed Phase 3 clinical trial in patients with schizophrenia, as well as data from the ITI-007 Positron Emission Tomography (PET) study in patients with schizophrenia.

The Company’s presentations at SIRS will include:

Oral Presentation: “Positive Phase 3 Clinical Trial of ITI-007 for the Treatment of Schizophrenia: Efficacy Results from a Randomized, Double-Blind, Placebo-Controlled Trial,” will be presented by Kimberly E. Vanover, Ph.D., Senior Vice President of Clinical Development during the Clinical Trial Session on Tuesday, April 5th from 6:15 pm to 6:30 pm local time. Location: Affari, Lower Level.

Poster presentation #S66: “ITI-007 Exhibits Unique Pharmacology: Combined Results from Positron Emission Tomography (PET) Studies in Healthy Volunteers and Patients with Schizophrenia,” will be presented on Sunday, April 3rd from 11:00 am to 1:00 pm, local time. Location: Cavaniglia Pavilion, Poster Session I.

Poster presentation #M67: “Positive Phase 3 Clinical Trial of ITI-007 for the Treatment of Schizophrenia: Secondary Endpoints and Subgroup Analyses from a Randomized, Double-Blind, Placebo-Controlled Trial,” will be presented on Monday, April 4th from 11:00 am to 1:00 pm local time.  Location: Cavaniglia Pavilion, Poster Session II.

Poster presentation #T66: “Positive Phase 3 Clinical Trial of ITI-007 for the Treatment of Schizophrenia: Safety Results from a Randomized, Double-Blind, Placebo-Controlled Trial,” will be presented on Tuesday, April 5th from 11:00 am to 1:00 pm local time. Location: Cavaniglia Pavilion, Poster Session III.

About Intra-Cellular Therapies

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in dementia, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia and bipolar depression. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.

Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, our clinical and non-clinical development plans; the progress, timing and results of our clinical trials; the safety and efficacy of our product development candidates; our beliefs about the potential uses and benefits of ITI-007; and our research and development efforts and plans under the caption "About Intra-Cellular Therapies." All such forward-looking statements are based on management's present expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include but are not limited to the following: our current and planned clinical trials, other studies for ITI-007, and our other product candidates may not be successful or may take longer and be more costly than anticipated; product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials; our reliance on collaborative partners and other third parties for development of our product candidates; and the other risk factors detailed in our public filings with the Securities and Exchange Commission. All statements contained in this press release are made only as of the date of this press release, and we do not intend to update this information unless required by law.

Contact:
Juan Sanchez, M.D. 
Vice President 
Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc. 
Phone: 646-440-9333

Burns McClellan, Inc. 
Lisa Burns 
Justin Jackson (Media)
[email protected]
212-213-0006